6phf: Difference between revisions
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
<StructureSection load='6phf' size='340' side='right'caption='[[6phf]], [[Resolution|resolution]] 3.10Å' scene=''> | <StructureSection load='6phf' size='340' side='right'caption='[[6phf]], [[Resolution|resolution]] 3.10Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[6phf]] is a 6 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6PHF OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6PHF FirstGlance]. <br> | <table><tr><td colspan='2'>[[6phf]] is a 6 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human] and [http://en.wikipedia.org/wiki/Plafa Plafa]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6PHF OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6PHF FirstGlance]. <br> | ||
</td></tr><tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[6phb|6phb]]</td></tr> | </td></tr><tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[6phb|6phb]]</td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6phf FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6phf OCA], [http://pdbe.org/6phf PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6phf RCSB], [http://www.ebi.ac.uk/pdbsum/6phf PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6phf ProSAT]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6phf FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6phf OCA], [http://pdbe.org/6phf PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6phf RCSB], [http://www.ebi.ac.uk/pdbsum/6phf PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6phf ProSAT]</span></td></tr> | ||
</table> | </table> | ||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
Transmission-blocking vaccines have the potential to be key contributors to malaria elimination. Such vaccines elicit antibodies that inhibit parasites during their development in Anopheles mosquitoes, thus breaking the cycle of transmission. To date, characterization of humoral responses to Plasmodium falciparum transmission-blocking vaccine candidate Pfs25 has largely been conducted in pre-clinical models. Here, we present molecular analyses of human antibody responses generated in a clinical trial evaluating Pfs25 vaccination. From a collection of monoclonal antibodies with transmission-blocking activity, we identify the most potent transmission-blocking antibody yet described against Pfs25; 2544. The interactions of 2544 and three other antibodies with Pfs25 are analyzed by crystallography to understand structural requirements for elicitation of human transmission-blocking responses. Our analyses provide insights into Pfs25 immunogenicity and epitope potency, and detail an affinity maturation pathway for a potent transmission-blocking antibody in humans. Our findings can be employed to guide the design of improved malaria transmission-blocking vaccines. | |||
Potent antibody lineage against malaria transmission elicited by human vaccination with Pfs25.,McLeod B, Miura K, Scally SW, Bosch A, Nguyen N, Shin H, Kim D, Volkmuth W, Ramisch S, Chichester JA, Streatfield S, Woods C, Schief WR, Emerling D, King CR, Julien JP Nat Commun. 2019 Sep 24;10(1):4328. doi: 10.1038/s41467-019-11980-6. PMID:31551421<ref>PMID:31551421</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
</div> | |||
<div class="pdbe-citations 6phf" style="background-color:#fffaf0;"></div> | |||
== References == | |||
<references/> | |||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: Human]] | |||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
[[Category: Plafa]] | |||
[[Category: Julien, J P]] | [[Category: Julien, J P]] | ||
[[Category: McLeod, B R]] | [[Category: McLeod, B R]] | ||
Revision as of 09:18, 10 October 2019
Pfs25 in complex with the human transmission blocking antibody 2587Pfs25 in complex with the human transmission blocking antibody 2587
Structural highlights
Publication Abstract from PubMedTransmission-blocking vaccines have the potential to be key contributors to malaria elimination. Such vaccines elicit antibodies that inhibit parasites during their development in Anopheles mosquitoes, thus breaking the cycle of transmission. To date, characterization of humoral responses to Plasmodium falciparum transmission-blocking vaccine candidate Pfs25 has largely been conducted in pre-clinical models. Here, we present molecular analyses of human antibody responses generated in a clinical trial evaluating Pfs25 vaccination. From a collection of monoclonal antibodies with transmission-blocking activity, we identify the most potent transmission-blocking antibody yet described against Pfs25; 2544. The interactions of 2544 and three other antibodies with Pfs25 are analyzed by crystallography to understand structural requirements for elicitation of human transmission-blocking responses. Our analyses provide insights into Pfs25 immunogenicity and epitope potency, and detail an affinity maturation pathway for a potent transmission-blocking antibody in humans. Our findings can be employed to guide the design of improved malaria transmission-blocking vaccines. Potent antibody lineage against malaria transmission elicited by human vaccination with Pfs25.,McLeod B, Miura K, Scally SW, Bosch A, Nguyen N, Shin H, Kim D, Volkmuth W, Ramisch S, Chichester JA, Streatfield S, Woods C, Schief WR, Emerling D, King CR, Julien JP Nat Commun. 2019 Sep 24;10(1):4328. doi: 10.1038/s41467-019-11980-6. PMID:31551421[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. References
|
| ||||||||||||||||